Open AccessHumoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Author(s) -
Hana M. El Sahly,
Lindsey R. Baden,
Brandon Essink,
David C. Montefiori,
Adrian McDermont,
Richard Rupp,
Michael I. Lewis,
Shobha Swaminathan,
Carl Griffin,
Veronica Fragoso,
Vicki E. Miller,
Bethany Girard,
Yamuna Devi Paila,
Weiping Deng,
Joanne E. Tomassini,
Robert Paris,
Florian Schödel,
Rituparna Das,
Allison August,
Brett Leav,
Jacqueline M. Miller,
Honghong Zhou,
Rolando Pajón
Publication year - 2022
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiac188
Subject(s) - immunogenicity , medicine , placebo , immune system , neutralizing antibody , antibody , immunology , coronavirus , serology , titer , virology , covid-19 , disease , infectious disease (medical specialty) , pathology , alternative medicine
Messenger RNA (mRNA)-1273 vaccine demonstrated 93.2% efficacy against coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial. The humoral immunogenicity results are now reported.